Story perspectives

Alnylam Unveils Bold '2030 Plan' for Growth and Innovation

1/12/2026

Summary

Story summary

Alnylam Pharmaceuticals announced on January 11, 2026, a five-year plan named Alnylam 2030 to drive innovation and growth.
CEO Yvonne Greenstreet highlighted a sustainable innovation engine and strong commercial performance.
Amvuttra quarterly sales falling short of expectations informs the plan's aim to deliver two new billion-dollar medicines, invest 30% of sales in research and development, and achieve 25% annual sales growth with a 30% operating margin excluding one-time costs.

1 of 1

Story summary

Alnylam Pharmaceuticals announced on January 11, 2026, a five-year plan named Alnylam 2030 to drive innovation and growth.
CEO Yvonne Greenstreet highlighted a sustainable innovation engine and strong commercial performance.
Amvuttra quarterly sales falling short of expectations informs the plan's aim to deliver two new billion-dollar medicines, invest 30% of sales in research and development, and achieve 25% annual sales growth with a 30% operating margin excluding one-time costs.